Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Taysha Gene Therapies (TSHA) to $19 from $13 and keeps an Overweight rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Citizens JMP healthcare analysts hold an analyst/industry conference
- FDA appoints Richard Pazdur as Director of CDER
- Taysha Gene Therapies price target raised to $8 from $6 at Citizens JMP
- Taysha Gene Therapies Advances TSHA-102 Program
- Taysha Gene Therapies’ Earnings Call Highlights Progress and Challenges